Lung, Phase I-II

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Sarah Goldberg

sarah.goldberg@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology

Sub-Investigators

Last Updated
08/07/2024
Study HIC
#2000035521